Nickel (II), a ubiquitous environmental and industrial contaminant, is a well-known human carcinogen, particularly in human lung cancer. Although by itself it is a weak mutagen, nickel (II) is able to significantly enhance the genotoxicity of other mutagens and carcinogens, such as polycyclic aromatic hydrocarbons (PAHs) and ultraviolet light. Certain human populations, especially cigarette smokers, are frequently exposed to both nickel (II) and PAHs. To understand the interplay of nickel (II) and PAHs in mutagenesis and human carcinogenesis, we used a shuttle vector mutagenicity assay to examine the effect of nickel (II) on (AE) anti-7b, 8a-dihydroxy-9a, 10a-epoxy-7,8,9,10-tetrahydroxybenzo[a]pyrene (BPDE)-induced mutagenesis in human cells. BPDE is an activated metabolite of benzo[a]pyrene (BP), a major carcinogen in cigarette smoke. The shuttle vector pSP189 modified with BPDE was transfected into human cells with and without nickel (II) exposure. We found that nickel (II) exposure significantly enhanced BPDE-induced mutation frequency, but did not change BPDE-induced mutational spectrum in the supF gene of pSP189 plasmids replicated in nucleotide excision repair (NER)-proficient human cells. However, the enhancing effect of nickel (II) on BPDE-induced mutation frequency was not observed in NER-deficient human XPA cells. We also found that nickel (II) exposure of human cells did not change the spontaneous mutation frequency of the supF gene in NER-proficient or NERdeficient human cells, indicating that nickel (II) did not affect the replication fidelity in human cells. Using a plasmid containing a luciferase reporter gene and a host cell reactivation assay, we have found that nickel (II) exposure greatly inhibited the repair of BPDEEEDNA adducts in NER-proficient but not in NER-deficient cells. Together these results strongly suggest that nickel (II) can greatly enhance the mutagenicity and genotoxicity of PAHs by inhibiting the NER pathway in human cells, and this may constitute an important mechanism for nickel (II)-induced human carcinogenesis.
Introduction
Nickel (II) is a ubiquitous environmental and industrial contaminant (1, 2) . It is widely used in industrial processes, such as electroplating and the manufacture of steel and batteries (1, 2) . Epidemiological studies have shown that occupational exposure to nickel (II) is strongly associated with a high incidence of human lung and nasal cancers (2, 3) . Nickel (II) can also cause cell transformation and induce tumors in animal models (4EE7). Lung and kidney are the major target organs for both soluble and insoluble forms of nickel (II) in humans as well as rodents (3, 5, 8) . Although nickel (II) is a well-known carcinogen in humans and animals, the underlying molecular mechanisms of nickel (II)-induced carcinogenesis are not yet well understood.
It has been shown that nickel (II) by itself causes little or no damage to naked DNA, and it is not mutagenic in bacterial test systems and only a weak mutagen in cultured mammalian cells (1, 9EE11) . However, nickel (II) is able to significantly enhance the genotoxicity of some other DNA damaging agents. For example, it has been found that nickel chloride treatment can increase ultraviolet (UV) light-induced mutation frequencies of the hypoxanthine (guanine) phosphoribosyl-transferase (hprt) gene and sister-chromatid exchanges in V79 Chinese hamster cells, and can enhance morphological transformation induced by benzo[a]pyrene (BP), a major carcinogen in cigarette smoke, in hamster embryo cells (11, 12) . Intriguingly, however, nickel (II) treatment, under conditions that induce high levels of cytotoxicity, has been reported to reduce (AE) anti-7b, 8a-dihydroxy-9a, 10a-epoxy-7,8,9,10-tetrahydroxybenzo[a]pyrene (BPDE), an activated metabolite of BP-induced mutations in the hprt gene in human fibroblasts (13) . It thus appears that in human cells, nickel (II) treatment induces pleiotropic effects that are influenced by the experimental conditions used.
Cigarette smoke contains a substantial amount of nickel; up to 600 ng of nickel have been found in the main stream of smoke generated per cigarette (14) . The exact chemical form of nickel in cigarette mainstream smoke has not yet been established. Cigarette smoking is known to be the leading cause of human lung cancer; 90% of lung cancer-related deaths have been attributed to cigarette smoking (15, 16) . Polycyclic aromatic hydrocarbons (PAHs), the major carcinogens in cigarette smoke and widespread environmental pollutants present in all combustive products of organic materials have been suggested as being responsible for the initiation and development of human lung cancer (17) . We have found recently that various diol epoxides of PAHs present in cigarette smoke, including BPDE, preferentially form DNA adducts at mutational hotspots in the human p53 and K-ras genes, the two most commonly mutated genes in smoking-related lung cancers (18EE21). Furthermore, we have also found that the DNA adducts formed at these mutational hotspots are poorly repaired (21, 22) . These findings provide us with direct molecular links between the cigarette carcinogen PAHs and lung carcinogenesis.
PAHs are strong mutagens in almost all biological systems. PAHEEDNA adducts are able to block DNA replication and transcription and induce various mutations, notably G to T transversions (18, 23EE26) . Nickel (II), on the other hand, although by itself a weak mutagen, can enhance UV lightinduced mutagenicity and carcinogenicity (1, 11, 27) . These findings raise several interesting and important questions: what are the mechanisms underlying nickel (II)-induced carcinogenicity? Is nickel (II) a co-mutagen and/or co-carcinogen of PAHs? If so, then what are the mechanisms through which nickel (II) exerts its effects on PAH-induced mutagenesis and carcinogenesis? Since certain human populations, especially cigarette smokers, are frequently exposed to both nickel (II) and PAHs, answering these questions is crucial for understanding cigarette smoke-induced carcinogenesis.
To address these questions, we used a shuttle vector pSP189, containing a supF gene as a mutational target, to determine the effect of nickel (II) on BPDEEEDNA adduct-induced mutagenesis in human cells. We found that nickel (II) exposure of human cells significantly enhanced BPDEEEDNA adductinduced mutation frequency of the supF gene, but did not change the mutational spectrum. Using a host cell reactivation assay with a plasmid containing a luciferase reporter gene, we further examined the possible mechanisms through which nickel (II) exerts its effects on the mutagenicity of BPDEEE DNA adducts in human cells, and we found that nickel (II) greatly inhibited the nucleotide excision repair (NER) of BPDEEEDNA adducts in human cells.
Materials and methods

Plasmids
The shuttle vector pSP189, which contains the supF gene as a mutational target, was kindly provided by Dr Michael Seidman (NIA, NIH, Baltimore, MD) (28) . The pGL3-luciferase reporter vector containing a coding region for firefly luciferase (Catalog number E1741), and the pSV-b-galactosidase control vector containing the bacterial lacZ gene, which codes for b-galactosidase were purchased from Promega (Madison, WI).
Cells and cell cultures SV-40-transformed NER-deficient human XPA fibroblasts (XP12BE) and NER-proficient human fibroblasts (GM00637) were obtained from NIGMS Human Genetic Cell Repository (Camden, NJ). These cells were grown in Minimum Essential Medium supplemented with 10% fetal bovine serum in a 5% CO 2 humidified incubator.
Colony formation ability assay
Logarithmically growing NER-deficient human XPA fibroblasts (XP12BE) and NER-proficient human fibroblasts (GM00637) were incubated with various concentrations of nickel chloride, NiCl 2 (Sigma, St Louis, MO), for 24 h at 37 C in an incubator. After incubation, cells were immediately trypsinized and 300 cells/dish were seeded to test for colony formation ability. After 9 days of incubation, colonies were fixed with methanol, stained with crystal violet and counted. Colony formation ability was calculated based on plating efficiency of NiCl 2 -treated cells versus plating efficiency of untreated control cells.
Modification of plasmids with BPDE BPDE was purchased from Chemsyn Science Laboratories (Lenexa, KS). The plasmids pSP189 and pGL3-luciferase were modified with BPDE as described previously (29) . Briefly, purified plasmids were modified with various concentrations of BPDE at 25 C for 2 h, and the reactions were stopped by repeated phenol and diethyl ether extractions to remove the unreacted BPDE. DNA was then ethanol precipitated and dissolved in TE [10 mM Tris, 1 mM EDTA (pH 7.5)].
SupF mutagenesis assay
Human NER-deficient XPA fibroblasts (XP12BE) and NER-proficient fibroblasts (GM00637) were grown to 70% confluence in 150 mm tissue-culture dishes. Various concentrations of NiCl 2 was added to the culture medium, and the cells were then incubated at 37 C for 24 h. NiCl 2 was then removed and the pSP189 plasmids with and without BPDE modification were transfected into cells using Lipofectamine (Invitrogen, Carslbad, CA), according to manufacturer's instructions. Briefly, cells were transfected with a mixture of plasmids (40 mg) and Lipofectamine for 6 h. After transfection, medium containing the transfection mixture was removed and cells were cultured in fresh medium in the presence of NiCl 2 at the pre-treatment concentrations for another 60 h. The transfected plasmids were then rescued from the human cells by the alkaline lysis method described previously by Lee et al. (30) . Briefly, cells were trypsinized, washed and resuspended in suspension buffer (50 mM TrisEEHCl, pH 8.0, 10 mM EDTA, 100 mg/ml RNase A), mixed with lysis buffer (0.2 M NaOH, 1% SDS), incubated on ice for 15 min and neutralization buffer (3 M potassium acetate, pH 5.5) was added. After incubation at room temperature for 15 min, the mixture was centrifuged for 10 min at 16 000 g and the supernatant was extracted with phenol and chloroform and then precipitated with ethanol. The DNA was resuspended and treated with the DpnI restriction enzyme (New England Biolabs, Beverly, MA) to remove the unreplicated plasmids containing the bacterial adenine methylation pattern. The replicated plasmids were then electroporated into indicator MBM7070 bacteria, which carry a lacZ gene with an amber mutation. The transformed bacteria were plated on LuriaEEBertani broth plates containing ampicillin (50 mg/ml), isopropyl b-d-thiogalactoside (IPTG) (190 mg/ml) and 5-bromo-4-chloro-3-indolyl b-d-galactoside (X-Gal) (0.8 mg/ml). After overnight incubation at 37 C, white and light blue mutant colonies were picked from the background of blue wild-type colonies and re-streaked; the plasmids were then extracted and purified using QIApre-spin Plasmid Kit (Qiagen, Valencia, CA). The sequences of the supF gene of mutant plasmids were determined with the primer 5
H -GGC GAC ACG GAA ATG TTG AA-3 H and CEQ Dye Terminator Cycle Sequencing Kit (Beckman Coulter, Fullerton, CA), using the CEQ 2000XL Automatic DNA Analyser (Beckman Coulter).
Host cell reactivation assay
Human NER-deficient XPA fibroblasts (XP12BE) and NER-proficient fibroblasts (GM00637) were plated in triplicate in 60 mm dishes at a density of 3 Â 10 5 cells/dish and exposed to various concentrations of NiCl 2 at 37 C for 24 h. The cells were then transfected with 2 mg of pGL3-luciferase reporter plasmid modified with various concentrations of BPDE, using FuGENE 6 transfection reagent (Boehringer Mannheim, Indianapolis, IN). The untreated pSV-b-galactosidase control vector (0.5 mg), a b-galactosidase-expressing plasmid, was co-transfected into human cells as an internal control to normalize transfection efficiency. After transfection for 3 h, medium containing the transfection mixture was removed and cells were incubated in fresh medium in the presence of NiCl 2 at the pre-treatment concentrations for another 24 h. Cells were then lysed with 600 ml of Reporter Lysis Buffer (Promega). Transient expression of luciferase was determined by mixing 50 ml of cell extract with 100 ml of Luciferase Assay Reagent (Promega) and measuring the light emission with a luminometer (Wallac 1420 Victor 2 multilable counter system, Gaithersburg, MD). Transient expression of b-galactosidase was determined using the b-galactosidase Enzyme Assay System (Promega). Values of luciferase expression were normalized to the b-galactosidase control and averaged over the triplicates. Since the reporter gene will not be expressed unless BPDEEEDNA adducts are repaired by cells, this assay can be used to detect the repair capacity of cells. The relative luciferase activity (i.e. reactivation of the damaged plasmids by the host cells) from BPDE-treated pGL3-luciferase reporter plasmids is expressed as a percentage of luciferase activity from untreated pGL3-luciferase reporter plasmids and is used to represent the repair capacity of cells.
Results
It has been found that nickel (II) treatment can significantly enhance UV light-induced mutagenesis and BPDE-induced cell transformation, sister-chromatid exchange and ouabainresistant mutations (11, 12, 27) . On the other hand, it was reported that human cells treated first with nickel (II) and then with BPDE produced fewer hprt mutants than cells treated with BPDE alone (13) . In contrast, human cells treated first with BPDE and then with nickel (II) produced much more hprt mutants than cells treated with BPDE alone (13) . Intriguingly, the combination of BPDE and nickel (II) treatment, regardless of the sequence of treatment, caused similar increases in the level of cytotoxicity over either nickel (II) or BPDE treatment alone (13) . Together these results suggest that nickel (II) may have two effects on cell physiology: (i) nickel (II) may affect the fidelity of DNA replication, particularly translesion synthesis and/or the efficiency of DNA repair and (ii) the cytotoxic effect of nickel (II) could be mostly independent of its genotoxic effect, and BPDE may enhance the cytotoxicity of nickel (II). This study attempted to determine the effect of nickel (II) treatment on BPDEEEDNA adduct-induced mutagenesis and elucidate the mechanisms of how nickel (II) affects BPDEEEDNA adductinduced mutagenesis. We have chosen the shuttle vector pSP189EEhuman cell transfection system for this study.
Nickel (II) induced cytotoxicity in NER-proficient and NER-deficient human fibroblasts
In order to choose a nickel (II) treatment condition that minimizes the cytotoxic effects of nickel (II) but still allows for detectable levels of effect on mutagenesis and DNA repair, we first determined the cytotoxicity of NiCl 2 in NER-proficient human fibroblasts (GM00637) and NER-deficient XPA (XP12BE) fibroblasts. It has been established that the uptake of soluble nickel (II) by cells is a slow process and it takes 16EE24 h to reach the plateau (9) . We, therefore, treated the cells with various concentrations of NiCl 2 for 24 h to achieve a maximal level of nickel (II) uptake by cells. The dose effect of NiCl 2 cytotoxicity in NER-proficient and NER-deficient human fibroblasts is shown as colony formation ability in Table I . There are no statistically significant differences in NiCl 2 -induced cytotoxicity between NER-proficient and NER-deficient cells (P 4 0.05). After 24 h exposure, the colony formation ability is only slightly decreased at the concentration of 300 mM NiCl 2 , and it drops to 76 AE 4% in NER-proficient and 69 AE 5% in NER-deficient human cells, respectively. Thereafter, it drops to 52 AE 6 and 39 AE 3% at 500 mM NiCl 2 treatment, and to 23 AE 2 and 15 AE 4% at 750 mM NiCl 2 treatment in NER-proficient and NER-deficient human cells, respectively. Based on the results presented in Table I , subtoxic dosage up to 300 mM NiCl 2 was used in the following mutagenesis and repair studies.
Effect of nickel (II) on BPDE-induced mutation frequency in supF gene in NER-proficient and NER-deficient human fibroblasts To determine the effect of nickel (II) on BPDE-induced mutagenesis in human cells, NER-proficient human fibroblasts (GM00637) were exposed to 50 and 300 mM of NiCl 2 for 24 h, and then transfected with the shuttle vector pSP189 modified with 3 or 15 mM of BPDE. The transfected cells were further incubated in the presence of NiCl 2 at the pre-treatment concentrations for another 60 h. The progeny plasmids were then rescued and transformed into indicator bacteria MBM7070 to identify plasmids carrying mutations in the supF gene. The mutation frequency of the supF gene was defined as the ratio of the number of white or light blue mutant colonies to the total number of bacterial colonies obtained on indicator plates containing IPTG and X-Gal. Results in Table II show that NiCl 2 exposure does not change the mutation frequencies of the supF gene in BPDE-untreated pSP189 plasmids replicated in either NER-proficient or NER-deficient human fibroblasts. This result suggests that nickel (II) itself has a very weak mutagenic effect in human cells, which is consistent with previous reports (1,9, 31EE33). However, nickel (II) exposure shows enhancement of BPDEEEDNA adduct-induced supF mutation frequency in pSP189 plasmids replicated in NER-proficient human fibroblasts. While 50 mM NiCl 2 exposure shows no significant enhancing effects on BPDEEEDNA adduct-induced supF mutation frequency, 300 mM NiCl 2 exposure increases mutation frequency of supF gene from 10.4 AE 1.6 Â 10 À4 to 18.4 AE 2.1 Â 10 À4 (P 5 0.05) for pSP189 plasmids treated Logarithmically growing cells were treated with NiCl 2 for 24 h, trypsinized and reseeded for the determination of the colony formation ability. The data represent three independent experiments. The statistical difference between NER-proficient (GM00637) and NER-deficient (XPA) human fibroblasts is P40.05. with 3 mM BPDE, and from 37.6 AE 4.7 Â 10 À4 to 75.5 AE 3.5 Â 10 À4 (P 5 0.001) for plasmids treated with 15 mM BPDE. These results demonstrate that NiCl 2 exposure can significantly enhance the mutagenicity of BPDE in NER-proficient human fibroblasts.
Two possible mechanisms can account for the enhancement of BPDE-induced mutagenesis by nickel (II) in human cells: intracellular nickel (II) may affect the repair efficiency of BPDEEEDNA adducts, and/or may affect the fidelity of DNA replication. As nickel (II) exposure does not change the mutation frequency of untreated pSP189 plasmids replicated in either NER-proficient or NER-deficient human cells, it is unlikely that the enhancement of BPDE-induced mutagenesis in nickel (II)-treated cells is due to the decrease in DNA replication fidelity in nickel (II)-treated cells.
NER is the major pathway for repairing bulky BPDEEEDNA adducts in human cells, the enhancement of BPDE-induced mutagenesis by nickel (II) in human cells could be caused by the inhibition of NER by nickel (II). If this is the case, then nickel (II) treatment of NER-deficient cells should not affect BPDE-induced mutagenesis in NER-deficient cells. Results in Table II and Figure 1 show that the mutation frequency of the supF gene in BPDE-treated plasmids replicated in NER-deficient XPA fibroblasts without NiCl 2 exposure is much higher than the mutation frequency observed in BPDE-treated plasmids replicated in NER-proficient human fibroblasts without NiCl 2 exposure; these results are consistent with the current understanding that NER is the major pathway for repairing BPDEEEDNA adducts (34, 35) . The results, however, also clearly show that BPDEEEDNA adducts induce the same level of supF mutation frequency in XPA fibroblasts with and without NiCl 2 treatment. These findings that NiCl 2 exposure can enhance BPDEEEDNA adduct-induced mutagenesis in NER-proficient human fibroblasts but not in NER-deficient XPA fibroblasts strongly suggest that the enhancement of BPDEEEDNA adduct-induced mutagenesis by nickel (II) is the result of inhibition of the NER of BPDEEEDNA adducts by nickel (II) in human cells.
Effect of nickel (II) on the repair of BPDEEEDNA adducts in human cells
To further test the possibility that the enhancement of BPDEEEDNA adduct-induced mutagenesis by nickel (II) is caused by the inhibition of NER, a host cell reactivation assay was used to investigate the repair of BPDEEEDNA adducts in both NiCl 2 -treated and -untreated human cells. Plasmids containing a luciferase reporter gene (pGL3-luciferase) were modified with different concentrations of BPDE and transfected into NER-proficient and NER-deficient human cells with or without 300 mM NiCl 2 exposure, and the luciferase activity, which is proportional to the extent of expression of the reporter gene, was checked 24 h after transfection. As the reporter gene will not express unless BPDEEEDNA adducts are repaired by cells, the luciferase activity represents the extent of BPDEEEDNA adduct repair, which in turn reflects the cellular repair capacity of BPDEEEDNA adduct (36, 37) . The relative luciferase activity detected in NER-proficient and NER-deficient human cells with or without NiCl 2 treatment is presented in Figure 2 . The results show that when BPDE-modified plasmids were transfected into cells without NiCl 2 treatment, much higher luciferase activities were detected in NER-proficient cells than in NER-deficient cells, which indicates that the NER-proficient human cells can efficiently repair the BPDEEEDNA adducts from luciferase reporter plasmids while NER-deficient XPA cells do not, and that NER is a major pathway for the repair of BPDEEEDNA adducts. However, when these BPDE-modified plasmids were transfected into NiCl 2 -treated NER-proficient cells, much and NER-deficient XPA (XP12BE) (NEREE) human fibroblasts. BPDE-modified luciferase reporter plasmids (pGL3-luciferase) were transfected into NER-proficient and NER-deficient human fibroblasts with (solid lines, Ni) or without (broken lines, EENi) 300 mM NiCl 2 exposure for 24 h. After transfection for 3 h, cells were incubated in fresh medium for 24 h to allow DNA repair. Cells were then harvested and lysed, and the luciferase activity in the cells was measured. The relative luciferase activity, which represents the relative extent of BPDEEEDNA adduct repair at each condition, was determined as the percentage of luciferase activity expressed from BPDE-treated plasmids to that from untreated plasmids. The data represent three independent experiments. lower luciferase activities were detected as compared with NER-proficient cells without NiCl 2 treatment. In contrast, the same relative luciferase activities were detected when these BPDE-modified plasmids were transfected into NERdeficient cells with and without NiCl 2 treatment. These results are consistent with the above conclusion that NiCl 2 treatment inhibits DNA repair capacity and that NER is the target for nickel (II)-mediated repair inhibition.
We also determined the effect of concentration of nickel (II) on BPDEEEDNA adduct repair in NER-proficient cells. Luciferase activities were determined in cells first treated with different concentrations of NiCl 2 and then transfected with plasmids modified with 15 mM BPDE. Results in Figure 3 show that nickel (II) exerts a dose-dependent repair inhibition effect. Compared with cells without NiCl 2 exposure, at the concentration of 100 mM, NiCl 2 decreases relative repair capacity to 79 AE 7%; and at 300 mM, NiCl 2 decreases relative repair capacity to 14 AE 4%. However, the luciferase activity does not change significantly in cells treated with 550 mM NiCl 2 . These results are consistent with the observations, shown in Table II , that treatment of host cells with 50 mM does not enhance BPDEEEDNA adduct-induced mutation frequency, and only when host cells are treated with NiCl 2 at higher concentrations which are inhibitory to NER, BPDEEE DNA adduct-induced mutation frequency is enhanced.
Effect of nickel (II) exposure on the mutational spectrum of the supF gene in BPDE-treated pSP189 plasmids replicated in NER-proficient and NER-deficient human fibroblasts Previously, we have found that in the human p53 gene and K-ras genes, not only does BPDE preferentially form DNA adducts at positions corresponding to the major mutational hotspots in smoking-related lung cancers, but also BPDEEE DNA adducts formed at these positions are poorly repaired (19EE22). Since NER is the major pathway for the repair of BPDEEEDNA adducts, it is possible that the inhibition of the NER by nickel (II) may have sequence preference. If this is the case, NiCl 2 exposure may change the mutational spectrum induced by BPDEEEDNA adducts. To test this possibility the BPDEEEDNA adduct-induced mutational spectrum of the supF gene in human cells with or without NiCl 2 treatment was analyzed. Plasmids containing mutant supF were purified from 74 and 68 independent mutant pSP189 plasmids recovered after passage of the BPDE-modified pSP189 plasmids through NER-proficient human fibroblast cells with or without 300 mM NiCl 2 exposure, and the supF gene in these plasmids was sequenced. The types of mutations and the mutational spectrum induced by BPDEEEDNA adducts in the supF gene are presented in Table III 
Discussion
Both nickel (II) and PAHs are environmental contaminants that are also abundant in cigarette smoke (1, 2, 37) . It is well established that PAHs are mutagenic and tumorigenic, and the interactions of metabolically activated PAHs with DNA may be the trigger for mutagenesis and carcinogenesis (17, 18) . Although nickel (II)-containing compounds are weak Plasmids containing a luciferase reporter (pGL3-luciferase) were modified with 15 mM BPDE and transfected into NER-proficient (GM00637) human fibroblasts exposed to various concentrations of NiCl 2 for 24 h. After transfection for 3 h, the cells were incubated in fresh medium for another 24 h. Cells were then harvested and lysed, and the luciferase activity in the cells was measured. The relative luciferase activity expressed from BPDE-treated plasmids was determined as the percentage of luciferase activity expressed from untreated plasmids. The relative repair capacity was calculated as the percentage of the relative luciferase activity of the plasmids transfected in cells with NiCl 2 exposure to that in cells without NiCl 2 exposure. The data represent three independent experiments. Cigarette smokers and certain human populations are constantly exposed to both PAHs and nickel (II). It is thus important to understand the biological effects that result from exposure to both agents, such as cytotoxicity, mutagenicity, cell transformation and carcinogenicity. While it has been established that cells exposed to these two agents suffer higher than additive cytotoxicity regardless of the sequence of treatment with these two agents, there are conflicting reports regarding the effect of nickel (II) on PAH-induced mutagenesis (12, 13) . A co-mutagenic effect of NiSO 4 with BP has been detected in a somatic mutant resistant to ouabain in primary cultures of Syrian hamster embryos (12) . On the other hand, a recent report measuring the mutation frequency at the hprt gene found that Ni 3 S 2 pre-treatment was protective towards BPDE-induced mutagenicity in human fibroblasts (13) . The same report, however, also showed that when cells were treated with both nickel (II) and BPDE simultaneously the mutation frequency was synergistically increased (13) . However, the conditions used in the latter study led to very low colony formation ability of human cells after cells were combining treated with Ni 3 S 2 and BPDE, and seem to be inadequate for measuring mutation frequency at the hprt locus. In this study, we readdressed this question and determined the effects of nickel (II) on mutagenicity of PAHs in human cells, using a shuttle-vector mutagenicity assay. Our results demonstrate that nickel (II) exposure can enhance the mutagenicity of BPDEEEDNA adducts in human cells, and this effect is mainly the result of inhibition of NER by nickel (II). Most recently, using high performance liquid chromatography/fluorescence assay, Hartwig and his colleagues have also shown that nickel (II) can inhibit the removal of BPDEEEDNA adducts in human cells (45) .
Our conclusion that nickel (II) does not affect the fidelity of DNA replication in human cells is based on the following three findings: (i) nickel (II) exposure does not enhance the mutation frequency in supF of control pSP189 plasmids, (ii) nickel (II) exposure does not change the mutational spectrum of supF in BPDE-treated pSP189 plasmids in NER-proficient cells and (iii) nickel (II) exposure does not change BPDE-induced mutation frequency or mutational spectrum in NER-deficient XPA cells. Using a host-cell reactivation assay, we have found that nickel (II) exposure can greatly inhibit the NER capacity for BPDEEEDNA damage in human cells. Together these results lead us to conclude that the enhancement of nickel (II) on BPDEEEDNA adduct-induced mutagenesis is caused by its inhibition of the repair of BPDEEEDNA adducts rather than through an effect on the fidelity of DNA replication.
The underlying mechanisms of the inhibition of repair for BPDEEEDNA adducts by nickel (II) are not yet understood. It has been shown that nickel (II) can interfere with the initial incision and ligation steps of NER pathway in the repair of UV light-induced CPD, and the ligation of DNA strand breaks in the repair of radiation-induced DNA double-strand breaks (41, 42) . Nickel (II) can also inhibit repair of oxidative DNA damage, which presumably is repaired by base excision repair pathway (44) . The inhibitory effect of nickel (II) on such broad repair mechanisms at different steps of repair raises the possibility that nickel (II) exerts its inhibitory effect not through a specific protein but instead through co-factors that are necessary for different repair steps. Magnesium and zinc ions are two probable candidates. Magnesium ion mediates DNAE protein interactions in the damage recognition and incision step and is also a co-factor for DNA polymerases and DNA ligases in the polymerization and/or ligation steps in DNA repair (46) . Several repair proteins such as XPA and NEH1 contain zinc fingers, and zinc is thus essential for maintaining the structural integrity of these proteins (46EE49). It is possible that nickel (II) competes with and displaces essential metal ions involved in DNA repair, such as magnesium and zinc (9, 38, 46) . It has been found that the inhibitory effect of nickel (II) on CPD Fig. 4 . BPDEEEDNA adduct-induced mutational spectrum in the supF gene in pSP189 plasmids replicated in NER-proficient (GM00637) human fibroblasts with (lower panel) or without (upper panel) 300 mM NiCl 2 exposure. Methods for NiCl 2 exposure, transfection and supF gene mutation detection are described in Materials and methods. The mutation frequency in the supF gene of pSP189 plasmid replicated in NER-proficient (GM00637) human fibroblasts with NiCl 2 exposure is 75.5 AE 3.5 Â 10 À4 , and the mutation frequency is 38.9 AE 4.2 Â 10 À4 in human fibroblasts without NiCl 2 exposure. The mutant plasmids were purified (74 mutant plasmids from cells with NiCl 2 exposure and 68 mutants plasmids from cells without NiCl 2 exposure) and the supF gene in these plasmids was sequenced. X, single base deletions; , single base insertions; #, Ã , _, multiple mutations (two mutations occurring in the same plasmid).
repair can be partially reversed by the addition of magnesium (9, 46) . Nickel (II) has also been found to be able to displace zinc ion from zinc finger structures (50) . As XPA, a member of the protein complex of the NER pathway, that participates in the assembly of the damage recognition/incision complex, contains a zinc finger structure, the competition of zinc ion by nickel (II) might be relevant to the inhibition of DNA repair by nickel (II) (47) . Since nickel (II) is able to directly interact with amino acids and protein, it is also possible that nickel (II) directly interacts with repair proteins and proteins involved in regulating NER, and impairs their function in NER.
In summary, we have demonstrated that nickel (II) can greatly enhance BPDEEEDNA adduct-induced mutagenicity through inhibition of the NER pathway in human cells, and our results suggest that this inhibition by nickel (II) of DNA repair may play an important role in nickel (II)-induced human carcinogenesis, especially human lung carcinogenesis.
